# Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation

> **NCT01627223** · PHASE4 · TERMINATED · sponsor: **Taichung Veterans General Hospital** · enrollment: 17 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Lamivudine
- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT01627223
- **Lead sponsor:** Taichung Veterans General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Slow progress in recruiting study patients
- **Last updated:** 2016-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01627223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01627223, "Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01627223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*